714 related articles for article (PubMed ID: 8869862)
1. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
2. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
3. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ
Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty.
van den Bos AA; Deckers JW; Heyndrickx GR; Laarman GJ; Suryapranata H; Zijlstra F; Close P; Rijnierse JJ; Buller HR; Serruys PW
Circulation; 1993 Nov; 88(5 Pt 1):2058-66. PubMed ID: 8222099
[TBL] [Abstract][Full Text] [Related]
5. Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina.
Rupprecht HJ; Terres W; Ozbek C; Luz M; Jessel A; Hafner G; vom Dahl J; Kromer EP; Prellwitz W; Meyer J
J Am Coll Cardiol; 1995 Dec; 26(7):1637-42. PubMed ID: 7594097
[TBL] [Abstract][Full Text] [Related]
6. Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris. A controlled randomized double-blind pilot study.
Grip L; Blombäck M; Egberg N; Olsson A; Svane B; Velander M
Eur Heart J; 1997 Mar; 18(3):443-9. PubMed ID: 9076381
[TBL] [Abstract][Full Text] [Related]
7. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty.
Topol EJ; Bonan R; Jewitt D; Sigwart U; Kakkar VV; Rothman M; de Bono D; Ferguson J; Willerson JT; Strony J
Circulation; 1993 May; 87(5):1622-9. PubMed ID: 8491018
[TBL] [Abstract][Full Text] [Related]
8. The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease.
Linder R; Oldgren J; Egberg N; Grip L; Larson G; Siegbahn A; Wallentin L
Eur Heart J; 1999 Apr; 20(7):506-18. PubMed ID: 10365287
[TBL] [Abstract][Full Text] [Related]
9. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.
Topol EJ; Fuster V; Harrington RA; Califf RM; Kleiman NS; Kereiakes DJ; Cohen M; Chapekis A; Gold HK; Tannenbaum MA
Circulation; 1994 Apr; 89(4):1557-66. PubMed ID: 8149521
[TBL] [Abstract][Full Text] [Related]
10. In vivo thrombin generation and activity during and after intravenous infusion of heparin or recombinant hirudin in patients with unstable angina pectoris.
Merlini PA; Ardissino D; Rosenberg RD; Colombi E; Agricola P; Oltrona L; Ottani F; Galvani M; Bauer KA; Bottasso B; Bertocchi F; Mannucci PM
Arterioscler Thromb Vasc Biol; 2000 Sep; 20(9):2162-6. PubMed ID: 10978264
[TBL] [Abstract][Full Text] [Related]
11. Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty.
Meyer BJ; Fernández-Ortiz A; Mailhac A; Falk E; Badimon L; Michael AD; Chesebro JH; Fuster V; Badimon JJ
Circulation; 1994 Nov; 90(5):2474-80. PubMed ID: 7955205
[TBL] [Abstract][Full Text] [Related]
12. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
[TBL] [Abstract][Full Text] [Related]
13. Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects.
Lidón RM; Théroux P; Juneau M; Adelman B; Maraganore J
Circulation; 1993 Oct; 88(4 Pt 1):1495-501. PubMed ID: 8403297
[TBL] [Abstract][Full Text] [Related]
14. Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity.
Moser M; Ruef J; Peter K; Kohler B; Gulba DC; Paterna N; Nordt T; Kübler W; Bode C
J Thromb Thrombolysis; 2001 Oct; 12(2):165-9. PubMed ID: 11729368
[TBL] [Abstract][Full Text] [Related]
15. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
Gold HK; Torres FW; Garabedian HD; Werner W; Jang IK; Khan A; Hagstrom JN; Yasuda T; Leinbach RC; Newell JB
J Am Coll Cardiol; 1993 Apr; 21(5):1039-47. PubMed ID: 8459055
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators.
Circulation; 1997 Aug; 96(3):769-77. PubMed ID: 9264481
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostatic, and endothelium-derived parameters.
Suzuki S; Matsuo T; Kobayashi H; Matsuo M; Shimamo C; Koide M; Sakamoto S
Thromb Res; 2000 May; 98(4):269-79. PubMed ID: 10822073
[TBL] [Abstract][Full Text] [Related]
18. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators.
Serruys PW; Herrman JP; Simon R; Rutsch W; Bode C; Laarman GJ; van Dijk R; van den Bos AA; Umans VA; Fox KA
N Engl J Med; 1995 Sep; 333(12):757-63. PubMed ID: 7643882
[TBL] [Abstract][Full Text] [Related]
19. Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
Yusuf S
Am J Cardiol; 1999 Sep; 84(5A):20M-25M. PubMed ID: 10505539
[TBL] [Abstract][Full Text] [Related]
20. Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis.
Ohyama T; Hori T; Moriike M; Asano T; Hayashi H; Iwade K; Hosoda S
Thromb Haemost; 1998 Feb; 79(2):423-30. PubMed ID: 9493602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
